Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Firmagon

- PMLiVE

What oncologists really want from booth strategy

Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company  At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30...

Inizio

- PMLiVE

How smart spaces and real-time strategy transformed ASCO® 2025

Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs - it was also a showcase for how technology is redefining congress engagement. Supporting...

Inizio

- PMLiVE

The science is shifting in oncology: Are you ready to evolve with it?

Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic...

Inizio

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

Patient Recruitment in Oncology: A Phase III Melanoma Case Study

Boosting screening & enrollment rates in a global oncology trial

Innovative Trials

- PMLiVE

NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

- PMLiVE

Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

- PMLiVE

Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

The rare inherited disease affects approximately 11,000 people in the UK

- PMLiVE

Gilead Sciences and Kymera enter oncology partnership worth up to $750m

The companies will focus on advancing Kymera’s oral molecular glue degrader programme

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links